Aim
RidStress2 is a consumer-informed, double-blind, Phase 3 randomised controlled trial (RCT) in 300 women with SGA or suboptimally grown fetuses at term (Population) to test if SC (Intervention) vs placebo (Comparator) (i) reduces the relative risk of emergency CS for fetal distress by 33% (Primary Outcome) (ii) improves childhood neurodevelopmental outcomes at 2 years; and (iii) is cost-effective.
Progress
Recruitment of 282 participants across four south-east Queensland hospitals is now complete. Data analysis is in progress, as well as neurodevelopmental outcome follow up for the children of participants.
Level 3, Aubigny Place
Mater Research Institute
Raymond Terrace,
South Brisbane QLD 4101
The University of Queensland Faculty of Medicine